Athanor Capital, LP - TURNING POINT THERAPEUTICS I ownership

TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 196 filers reported holding TURNING POINT THERAPEUTICS I in Q4 2020. The put-call ratio across all filers is 0.56 and the average weighting 0.3%.

Quarter-by-quarter ownership
Athanor Capital, LP ownership history of TURNING POINT THERAPEUTICS I
ValueSharesWeighting
Q1 2021$226,000
-72.0%
2,394
-63.8%
0.01%
-72.2%
Q4 2020$806,000
+8.3%
6,616
-22.4%
0.02%
-35.7%
Q3 2020$744,000
-18.6%
8,521
-39.8%
0.03%
-39.1%
Q2 2020$914,000
-21.1%
14,146
-23.9%
0.05%
-13.2%
Q4 2019$1,159,000
+29.5%
18,600
-21.8%
0.05%
-8.6%
Q3 2019$895,000
+66.7%
23,800
+80.3%
0.06%
-15.9%
Q2 2019$537,00013,2000.07%
Other shareholders
TURNING POINT THERAPEUTICS I shareholders Q4 2020
NameSharesValueWeighting ↓
venBio Partners LLC 708,233$44,116,00018.91%
Corriente Advisors, LLC 285,000$17,753,0009.54%
Cormorant Asset Management, LP 3,396,650$211,577,0008.44%
Opaleye Management Inc. 340,500$21,210,0004.16%
Orbimed Advisors 2,745,327$171,006,0002.44%
Parkman Healthcare Partners LLC 101,434$6,318,0001.82%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 35,000$2,179,0000.78%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 366,000$22,798,0000.73%
Artal Group S.A. 300,000$18,687,0000.72%
DAFNA Capital Management LLC 30,408$1,894,0000.65%
View complete list of TURNING POINT THERAPEUTICS I shareholders